Considering Neoadjuvant Chemotherapy Options in Bladder Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

In this peer-to-peer discussion Dr. Grivas and Dr. Palmbos examine the role of neoadjuvant chemotherapy in bladder cancer and weigh the various trial data guiding these treatment decisions.

In this peer-to-peer discussion, Petros Grivas, MD, PhD, of the Cleveland Clinic in Cleveland, Ohio, and Phillip L. Palmbos, MD, PhD, of the University of Michigan in Ann Arbor, Michigan, examine the role of neoadjuvant chemotherapy in bladder cancer, weighing the various trial data that guide these treatment decisions, with considerations for patient comorbidities.

Financial Disclosure:Dr. Grivas is a consultant for Genentech.

 

Recent Videos
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Those with CML should discuss adverse effects such as nausea or fatigue with their providers to help optimize their quality of life during treatment.
Patients with CML can become an active part of their treatment plan by discussing any questions that come to mind with their providers.
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content
Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Discerning the Best Frontline, Personalized Treatment in Urothelial Carcinoma

Alex Biese
November 20th 2024
Article

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Extended Lymphadenectomy Does Not Improve DFS/OS in Bladder Cancer

Tim Cortese
November 6th 2024
Article

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

FDA Accepts New Drug Application for UGN-102 for Bladder Cancer

Roman Fabbricatore
October 16th 2024
Article

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

TAS-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.

TAR-200 Study in Muscle-Invasive Bladder Cancer Discontinued

Ariana Pelosci
October 9th 2024
Article

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.